JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, Atopic | JNJLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 2NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, AtopicActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04009109Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMAlliance Foundation Trials, LLC. · Myeloma, MultipleActive, not recruitingBMYCollaboratorTAKCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05300451Daratumumab in HLA Desensitization Prior to TransplantationBarry A. Boilson · Cardiac TransplantEnrolling by invitationJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT06651489Efficacy of Guselkumab in Treating Hailey Hailey DiseaseYale University · Hailey Hailey DiseaseRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2/Phase 3NCT05327114Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC · Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimatePhase 2NCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseJanssen Pharmaceutica N.V., Belgium · Alzheimer DiseaseActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 2NCT06067269Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer...Jonsson Comprehensive Cancer Center · Prostate AdenocarcinomaRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 2NCT02436707Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaCanadian Cancer Trials Group · LymphomaActive, not recruitingKPTIQCollaboratorJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 2027Sponsor estimatePhase 2NCT04270175Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabWeill Medical College of Cornell University · AmyloidActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT06827860Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early RelapseLarysa Sanchez · Multiple Myeloma in RelapseRecruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT03902951Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerJonsson Comprehensive Cancer Center · Metastatic Prostate AdenocarcinomaActive, not recruitingJNJCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1/Phase 2NCT05908734A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 1, 2027Sponsor estimate | NCT04268498A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaUniversity of Miami · Multiple Myeloma | JNJCollaboratorAMGNCollaborator | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 1, 2027Sponsor estimatePhase 2NCT04268498A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaUniversity of Miami · Multiple MyelomaActive, not recruitingJNJCollaboratorAMGNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.